Group 1: Adobe Inc. Financial Results - Adobe reported second-quarter revenue of $5.87 billion, exceeding analyst estimates of $5.79 billion [1] - The company reported adjusted earnings of $5.06 per share, surpassing the estimated $4.96 per share [1] - Adobe raised its FY25 guidance following the positive financial results [1] Group 2: Stock Movements - Adobe shares fell 1.8% to $406.55 in pre-market trading [2] - Liminatus Pharma, Inc. shares tumbled 16.2% to $17.03 after a previous jump of over 82% [4] - Generation Essentials Group TGE fell 10.6% to $8.46 after a 14% dip on Thursday [4] - VEON Ltd shares dipped 9.9% to $42.36 after a 5% increase on Thursday [4] - Arrive AI Inc. fell 8.8% to $8.50 after gaining around 10% previously [4] - SEALSQ Corp LAES fell 7.3% to $3.94 in pre-market trading [4] - Planet Labs PBC PL fell 7.1% to $5.07 after announcing a seven-figure NATO contract [4] - Omada Health, Inc. OMDA dipped 6.8% to $16.00 in pre-market trading [4] - COMPASS Pathways plc CMPS fell 6% to $4.2500 in pre-market trading [4] - FibroGen, Inc. FGEN fell 4.4% to $0.2949 following a 1-for-25 reverse stock split [4]

Core Insights - The field of psychedelic medicine is emerging, attracting investor interest due to its potential for growth and innovation [1] - Compass Pathways experienced a 13% increase in share price following the announcement of a completed step in its clinical trial [1] Company Developments - Compass Pathways has completed dosing in a late-stage clinical trial for its psilocybin treatment, COMP005 [2] - The phase 3 trial involves 258 patients with moderate to severe depression who have not responded to at least two prior treatments, with dosing conducted at 32 sites in the U.S. [3][4] - The company is expected to publish six-week primary endpoint results by the end of June [3] Industry Context - The CEO of Compass Pathways emphasized the milestone as critical in addressing the unmet need in treatment-resistant depression, highlighting the legitimacy of psychedelics as potential therapies for serious psychological disorders [5]